These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32358915)

  • 1. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
    Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
    ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
    Asquith CRM; Laitinen T; Bennett JM; Wells CI; Elkins JM; Zuercher WJ; Tizzard GJ; Poso A
    ChemMedChem; 2020 Jan; 15(1):26-49. PubMed ID: 31675459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.
    Asquith CRM; Laitinen T; Bennett JM; Godoi PH; East MP; Tizzard GJ; Graves LM; Johnson GL; Dornsife RE; Wells CI; Elkins JM; Willson TM; Zuercher WJ
    ChemMedChem; 2018 Jan; 13(1):48-66. PubMed ID: 29072804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
    J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase.
    Martinez-Gualda B; Saul S; Froeyen M; Schols D; Herdewijn P; Einav S; De Jonghe S
    Eur J Med Chem; 2021 Mar; 213():113158. PubMed ID: 33497888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
    Kovackova S; Chang L; Bekerman E; Neveu G; Barouch-Bentov R; Chaikuad A; Heroven C; Šála M; De Jonghe S; Knapp S; Einav S; Herdewijn P
    J Med Chem; 2015 Apr; 58(8):3393-410. PubMed ID: 25822739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase.
    Martinez-Gualda B; Pu SY; Froeyen M; Herdewijn P; Einav S; De Jonghe S
    Bioorg Med Chem; 2020 Jan; 28(1):115188. PubMed ID: 31757682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
    Asquith CRM; Maffuid KA; Laitinen T; Torrice CD; Tizzard GJ; Crona DJ; Zuercher WJ
    ChemMedChem; 2019 Oct; 14(19):1693-1700. PubMed ID: 31424613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of isothiazolo[4,5-
    Ivanova Y; Spittaels S; Gao LJ; Schols D; Van Meervelt L; Froeyen M; Dehaen W; De Jonghe S
    Org Biomol Chem; 2024 Sep; 22(36):7373-7389. PubMed ID: 39171941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
    Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
    PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
    Pu SY; Wouters R; Schor S; Rozenski J; Barouch-Bentov R; Prugar LI; O'Brien CM; Brannan JM; Dye JM; Herdewijn P; De Jonghe S; Einav S
    J Med Chem; 2018 Jul; 61(14):6178-6192. PubMed ID: 29953812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
    Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).
    Asquith CRM; Berger BT; Wan J; Bennett JM; Capuzzi SJ; Crona DJ; Drewry DH; East MP; Elkins JM; Fedorov O; Godoi PH; Hunter DM; Knapp S; Müller S; Torrice CD; Wells CI; Earp HS; Willson TM; Zuercher WJ
    J Med Chem; 2019 Mar; 62(5):2830-2836. PubMed ID: 30768268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
    Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
    Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors.
    Perera BG; Maly DJ
    Mol Biosyst; 2008 Jun; 4(6):542-50. PubMed ID: 18493651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
    Araújo PM; da Silva LP; Esteves da Silva JC
    Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
    Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.